Holen Sie sich die Stockscreener-App
130.26
0.88%
1.14
Handel nachbörslich:
130.00
-0.26
-0.20%
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail
Mechanobiology-Centered Therapy Market Insights and Growth Outlook by Towards Healthcare - GlobeNewswire Inc.
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
Should You Buy Novartis Stock Before October 28? - Barchart.com
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail
2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva
Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Sahm
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm
Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs - The Globe and Mail
Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus
Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds - The Globe and Mail
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com
Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis
Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook - Sahm
BioArctic and Novartis Sign an Option, Collaboration and License Agreement Using BrainTransporter for an Upfront Payment of USD 30 Million Plus Additional Potential Milestones and Royalties - 富途牛牛
Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn
Will EXEL's Share Repurchase Program Boost Value for Investors? - The Globe and Mail
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
1.17%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):